Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bench

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Lancet (London, England)|March 23, 2005
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersE Joanna Baxter, Linda M Scott, Peter J Campbell, et al.
Haematologica|December 18, 2009
Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?Göran Mattsson, Susan H Turner, Jacqueline Cordell, et al.
Blood|May 31, 2002
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instabilityBrian J P Huntly, Anthony J Bench, Eric Delabesse, et al.
Nuclear Medicine and Biology|July 1, 1996
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PETS Osman, C Lundkvist, V W Pike, et al.
Blood|May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortPhilip A Beer, Peter J Campbell, Linda M Scott, et al.
Oncogene|August 22, 2000
Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG)A J Bench, E P Nacheva, T L Hood, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Lancet (London, England)|March 23, 2005
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersE Joanna Baxter, Linda M Scott, Peter J Campbell, et al.
Haematologica|December 18, 2009
Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?Göran Mattsson, Susan H Turner, Jacqueline Cordell, et al.
Blood|May 31, 2002
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instabilityBrian J P Huntly, Anthony J Bench, Eric Delabesse, et al.
Nuclear Medicine and Biology|July 1, 1996
Characterization of the radioactive metabolites of the 5-HT1A receptor radioligand, [O-methyl-11C]WAY-100635, in monkey and human plasma by HPLC: comparison of the behaviour of an identified radioactive metabolite with parent radioligand in monkey using PETS Osman, C Lundkvist, V W Pike, et al.
Blood|May 3, 2008
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohortPhilip A Beer, Peter J Campbell, Linda M Scott, et al.
Oncogene|August 22, 2000
Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG)A J Bench, E P Nacheva, T L Hood, et al.
British Journal of Haematology|January 28, 2009
Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clonesPhilip A Beer, Amy V Jones, Anthony J Bench, et al.
Blood|July 29, 2006
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformationPeter J Campbell, E Joanna Baxter, Philip A Beer, et al.
British Journal of Haematology|October 13, 2012
Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutationsAnthony J Bench, Helen E White, Letizia Foroni, et al.
Lancet (London, England)|December 6, 2005
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyPeter J Campbell, Linda M Scott, Georgina Buck, et al.
Pageof 14